CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Emerald Health Pharmaceuticals Appoints Neuroscience Expert Dr. Eduardo Candelario-Jalil

Life Sciences Review Life Sciences Review | Thursday, June 10, 2021
Tweet

Emerald Health Pharmaceuticals has added neuroscience specialist and innovator Eduardo Candelario-Jalil, PhD, to its Scientific Advisory Board.


FREMONT, CA: Emerald Health Pharmaceuticals Inc., a clinical-stage biotechnology firm building a new class of medicine to cure diseases with unmet medical requirements, has appointed neuroscience specialist and innovator Eduardo Candelario-Jalil, PhD, to its Scientific Advisory Board.


"We are honored to have Dr. Candelario-Jalil join our Scientific Advisory Board as we advance our research and clinical programs," said Eduardo Mu±oz, MD, PhD, Chief Scientific Officer of EHP. "His expertise and innovative work in neuroinflammatory mechanisms adds greatly to our outstanding team of world-class scientific experts, which includes Professor Giovanni Appendino, PhD, a key opinion leader in chemistry, and Rao Movva, PhD, a Novartis Distinguished Scientist."


Jim DeMesa, MD, MBA, EHPs President, and CEO added, "The addition of Dr. Candelario-Jalil will further expand and strengthen our ability to guide the development of our proprietary molecules with unique capabilities that can potentially modify and reverse disease progression in patients suffering from devastating neurodegenerative and autoimmune diseases. 


We look forward to his contributions as we continue to advance our learning and development efforts to more powerfully affect the pathways of these challenging diseases to achieve better therapeutic outcomes." 


In addition to his contribution to the EHP Scientific Advisory Board, Dr. Candelario-Jalils has helped conduct preclinical studies in his laboratories at the University of Florida connected to using the Company's technology for the potential treatment of stroke.


Emerald Health Pharmaceuticals is working on cannabinoid-derived product candidates to treat CNS, autoimmune, and other diseases. The Company owns two families of proprietary new chemical entities deduced from synthetic cannabidiol (CBD) and cannabigerol (CBG), which it has altered using rational drug design to impact verified receptors and pathways relevant to targeted disease. EHP-101, the Company's first drug product candidate, has entered Phase 2 clinical trials to treat systemic sclerosis, a severe condition of scleroderma, and multiple sclerosis. EHP-102, its second product candidate, is in preclinical development and aims to cure Parkinson's and Huntington's disease.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/emerald-health-pharmaceuticals-appoints-neuroscience-expert-dr-eduardo-candelariojalil--nwid-396.html